How we think about weight management and metabolic health: What comes next after GLP-1 medications like Ozempic, Wegovy, and Mounjaro? These drugs have already revolutionised obesity treatment, but science does not stop there. So, let’s explore what the next generation of treatments might look like.
Where We Are Now: The GLP-1 Era?
GLP-1 receptor agonists, such as semaglutide and tirzepatide, have shown unprecedented effectiveness in reducing body weight up to 15-25% in some cases. They work by mimicking gut hormones that regulate appetite, insulin secretion, and glucose levels.
But while they are a major breakthrough, they’re not a cure. People often regain weight if they stop treatment, and side effects like nausea or gastrointestinal issues can be a challenge. That’s why researchers and biotech companies are already working on the next wave of innovation.
What’s Coming Next? Emerging Therapies?
- Dual and Triple Agonists
After GLP-1, we now have dual agonists like tirzepatide, which also targets GIP. Next are triple agonists, which act on GLP-1, GIP, and glucagon receptors, potentially delivering even greater weight loss with improved metabolic control.
- Amylin Analogues
Amylin is a hormone that complements insulin and slows gastric emptying. Drugs like cagrilintide, used in combination with semaglutide, could enhance satiety and boost weight loss.
- Oral and Long-Acting Formulations
Injectable meds are effective, but the future includes oral GLP-1s and weekly or monthly injectables for greater convenience and adherence.
- Gene and Microbiome Therapies
Further down the line, we may see gene editing approaches or microbiome-based treatments that target gut bacteria to regulate appetite and metabolism naturally.
Behavioural and Digital Interventions
Medications alone are not the full picture. Tech-driven tools like AI-powered nutrition coaching, wearable metabolic trackers, and digital CBT (Cognitive Behavioural Therapy) are being paired with medication to create a more holistic, personalised approach.
The goal? Long-term behaviour change, not just short-term weight loss.
So, what’s next after GLP-1s?
We are heading into an exciting era where obesity is treated not just as a willpower issue but as a complex, chronic condition with science-based, multi-layered solutions.
The GLP-1 Revolution
Over the past few years, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) have dramatically changed the way we treat obesity. These medications mimic natural hormones that regulate hunger and blood sugar, helping many patients lose 15% or more of their body weight. However, while they have been hailed as a breakthrough, they come with limitations. Most require weekly injections, can be expensive, and may cause side effects such as nausea or gastrointestinal discomfort. Additionally, questions remain about how sustainable the weight loss is after stopping the medication. As a result, researchers are already looking ahead to what might come next in the evolution of obesity treatment.
Beyond GLP-1s: Multi-Agonist Therapies
One promising area of innovation is the development of dual and triple agonist drugs that target multiple hormone receptors simultaneously. A leading candidate, retatrutide, acts on GLP-1, GIP, and glucagon receptors. Early studies suggest it could lead to weight loss exceeding 24%, a step beyond what current GLP-1s can offer. By addressing multiple metabolic pathways, these medications may not only be more effective but also potentially reduce side effects, offering a more holistic solution for weight regulation.
Oral Medications: More Accessible Options
For many patients, injections are a significant barrier. That’s why oral GLP-1s, such as orforglipron, are gaining attention. These medications offer the benefits of GLP-1 agonists in a pill form, eliminating the need for needles and potentially improving adherence and accessibility. If proven safe and effective, they could dramatically expand the reach of obesity pharmacotherapy.
Targeting the Gut-Brain Axis
Another exciting area of research is the gut-brain axis—the complex communication network between the digestive system and the brain. Scientists are exploring new drugs that influence hunger-related hormones like PYY and ghrelin, aiming to create a sense of fullness without affecting metabolism directly. These treatments could help regulate appetite more naturally and potentially reduce the risk of rebound weight gain.
Genetics and the Microbiome: Treating the Root Causes
Advances in gene therapy and microbiome science are also pointing toward the future. Gene-editing technologies such as CRISPR hold the potential to reprogram how the body stores and burns fat at a genetic level. Simultaneously, therapies targeting gut bacteria may help modify metabolic responses and improve insulin sensitivity. While still in the early stages of development, these approaches aim to tackle the root biological causes of obesity rather than just managing symptoms.
The Rise of Personalized and Digital Medicine
Obesity treatment is also becoming more personalized. Using genetic testing, blood biomarkers, and artificial intelligence, future interventions may be tailored to each individual’s unique biology and lifestyle. This mirrors the trend in other areas of medicine, like oncology and cardiology, where precision therapies are becoming the norm. Additionally, digital health tools such as mobile apps, smart scales, and AI-powered coaching platforms are increasingly being used to support behavior change and long-term weight management.
Modern Surgery and Devices Still Matter
While medications are advancing rapidly, surgical and device-based options continue to evolve. Bariatric surgery remains the most effective long-term treatment for severe obesity, but newer, minimally invasive procedures are becoming more attractive. Temporary gastric balloons, endoscopic sleeve gastroplasty, and vagus nerve stimulators are among the tools being refined for safer and more accessible use. These interventions may increasingly be used in combination with medications as part of a comprehensive treatment plan.
A Multi-Modal Future for Obesity Care
Looking ahead, the future of obesity treatment is unlikely to rely on a single solution. Instead, we are moving toward a multi-modal, integrated approach that combines medications, behavioral support, digital tools, surgery, and possibly gene-based therapies. The goal is not only to achieve weight loss, but to make it sustainable, accessible, and free from stigma. GLP-1s have opened a crucial door in the fight against obesity. What comes next could completely reshape how we understand and treat this complex, chronic condition.
